Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells $266,625.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $21.33, for a total value of $266,625.00. Following the sale, the chief executive officer owned 902,892 shares of the company’s stock, valued at approximately $19,258,686.36. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.06, for a total value of $74,222.00.
• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.03, for a total value of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.25, for a total value of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $19.09, for a total value of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.02, for a total value of $208,067.86.

Enliven Therapeutics Price Performance

Shares of ELVN opened at $20.55 on Friday. The stock has a 50-day moving average of $20.15 and a 200-day moving average of $19.65. The company has a market cap of $1.22 billion, a PE ratio of -10.28 and a beta of 0.85. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $29.78.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. Analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently added to or reduced their stakes in ELVN. TCG Crossover Management LLC bought a new position in Enliven Therapeutics in the 2nd quarter valued at about $9,990,000. Duquesne Family Office LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,288,000. Candriam S.C.A. bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $8,358,000. Franklin Resources Inc. lifted its position in shares of Enliven Therapeutics by 2,029.3% during the 2nd quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after buying an additional 410,034 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $8,024,000. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

ELVN has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, July 2nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.